TY  - RPRT
TI  - Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
AU  - R Gervais
AU  - A Ducolone
AU  - J-L Breton
AU  - D Braun
AU  - B Lebeau
AU  - F Vaylet
AU  - D Debieuvre
AU  - J-L Pujol
AU  - J Tredaniel
AU  - P Clouet
AU  - E Quoix
PY  - 2005
DO  - 10.1093/annonc/mdi018
UR  - https://pubmed.ncbi.nlm.nih.gov/15598944/
ID  - 15598944
ER  -